Sorrento Therapeutics Inc

OTC: SRNEQ    
Share price (4/12/24): $0.03    
Market cap (4/12/24): $16.5 million
Search in Documents
Key Exhibits
External Links
4 Sorrento Therapeutics Inc Expert Interviews, now on BamSEC.
 Powered by Tegus.

Credit Agreements Filter

EX-10.1
from 8-K 49 pages Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement by and Among Sorrento Therapeutics, Inc. Scintilla Pharmaceuticals, Inc. as Borrowers, and Oramed Pharmaceuticals Inc., as Lender Dated as of August 9, 2023
12/34/56
EX-10.2
from 8-K 13 pages Intercreditor and Subordination Agreement
12/34/56
EX-10.1
from 8-K 16 pages July 5, 2023 Sorrento Therapeutics, Inc. Scintilla Pharmaceuticals, Inc. Debtor-In-Possession Term Loan Facility Summary of Terms and Conditions
12/34/56
EX-10.1
from 8-K 58 pages Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement by and Among Sorrento Therapeutics, Inc. Scintilla Pharmaceuticals, Inc. as Borrowers, and Jmb Capital Partners Lending, LLC, as Lender Dated as of March 30, 2023
12/34/56
EX-10.1
from 10-Q 14 pages Bridge Loan Agreement Dated as of February 16, 2022
12/34/56
EX-10.3
from 8-K 3 pages Loan Agreement
12/34/56
EX-10.2
from 8-K 4 pages 1 Loan Amount and Duration 1.1 the Loan Amounts Under This Contract Are Stated Below
12/34/56
EX-10.1
from 8-K 12 pages Consent Under and Amendment No. 3 to Indenture and Letter of Credit
12/34/56
EX-10.2
from 10-Q 9 pages *** Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit. *** Omnibus Amendment No. 2 to Indenture and Letter of Credit
12/34/56
EX-10.32
from 10-K 137 pages ***Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit. *** Amendment No. 2 to Term Loan Agreement
12/34/56
EX-10.1
from 8-K 11 pages *** Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Such Omitted Information Is Indicated by Brackets (“[...***...]”) in This Exhibit. *** Omnibus Amendment No. 1 to Indenture and Letter of Credit
12/34/56
EX-10.1
from 8-K 127 pages Certain Identified Information Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Such Omitted Information Is Indicated by Brackets ("[...***...]") in This Exhibit. *** Amendment No. 1 to Term Loan Agreement
12/34/56
EX-10.5
from 10-Q 98 pages Term Loan Agreement Dated as of November 7, 2018 Among Sorrento Therapeutics, Inc., as Borrower, Certain Subsidiaries of Sorrento Therapeutics, Inc., as Guarantors, Sc Investments Ne Holdings, LLC, Sc Investments E Holdings, LLC, Oaktree Strategic Income II, Inc., and Ocsl SRNE, LLC, as Lenders, and Oaktree Fund Administration, LLC, as Agent $150,000,000 Senior Secured First Lien Term Loan
12/34/56
EX-10.4
from 10-Q ~10 pages Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 Irrevocable Standby Letter of Credit
12/34/56
EX-10.3
from 10-Q 5 pages Seventh Amendment to Loan and Security Agreement
12/34/56
EX-10.2
from 10-Q 8 pages Consent and Sixth Amendment to Loan and Security Agreement
12/34/56
EX-10.1
from 10-Q 8 pages Fifth Amendment to Loan and Security Agreement
12/34/56
EX-10.31
from 10-K/A 48 pages Loan and Security Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Fourth Amendment to Loan and Security Agreement
12/34/56
EX-10.35
from 10-K/A 11 pages Third Amendment to Loan and Security Agreement
12/34/56